West Pharmaceutical Services Inc (WST) FinancialsWSTWest Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. (WST) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is High Value Components, accounting for 48.0% of total sales, equivalent to $405.55M. Other significant revenue streams include Standard Packaging and Contract-Manufactured Products. Understanding this composition is critical for investors evaluating how WST navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, West Pharmaceutical Services, Inc. maintains a gross margin of 37.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.40%, while the net margin is 17.65%. These profitability ratios, combined with a Return on Equity (ROE) of 19.09%, provide a clear picture of how effectively WST converts its operational activities into shareholder value.

In the context of the broader market, WST competes directly with industry leaders such as ALC and GH. With a market capitalization of $25.79B, it holds a significant position in the sector. When comparing efficiency, WST's gross margin of 37.74% stands against ALC's 60.50% and GH's 65.39%. Such benchmarking helps identify whether West Pharmaceutical Services, Inc. is trading at a premium or discount relative to its financial performance.

West Pharmaceutical has demonstrated solid financial performance with a Q2 2026 revenue of $872 million, reflecting a 13.8% year-over-year increase. The gross margin for Q2 2026 stands at 37.74%, showing effective cost management and profitability. The company has also raised its 2023 sales guidance to $3.375 billion, highlighting strong growth expectations.